Sleep and recovery changes
Often reported within 2–4 weeks.
Protocol / Research Dosing Guide
Sermorelin Dosage Guide: Nightly GHRH Schedule, Reconstitution and Safety
An evidence-organized Sermorelin reference that separates its historical FDA approvals and current compounding status from modern community titration practices.
Last reviewed September 16, 202617 minute readResearch information only
Level 5 — Formerly FDA approved, now compounded onlyBranded product discontinued503A Category 1 as of the source review date
Sermorelin Quick Start
Sermorelin copies the first 29 amino acids of natural GHRH, enough to trigger a pituitary GH pulse. It carries a genuine but historical FDA approval record: approved, then withdrawn from the market for manufacturing reasons rather than safety, and currently compoundable under 503A Category 1 rather than sold as an approved branded drug. Adult dosing beyond the original pediatric and diagnostic label was never validated by a large modern randomized trial.
Why researchers care
Growth hormone secretagogue research and GH/IGF-1 axis stimulation
Class
GHRH(1–29) analogue, a 29-amino-acid fragment of human growth hormone-releasing hormone
Route reported
Subcutaneous injection, typically nightly before bed
Cycle length
3–6 months at a target dose reported in practitioner reviews, with lab checks at baseline, week 6, and week 12
Regulatory status
FDA approved in 1990 as a diagnostic agent and in 1997 as Geref for childhood growth hormone deficiency; Geref was discontinued by Serono Laboratories in 2008 for manufacturing reasons; sermorelin remained on FDA's 503A Category 1 list as of the source review date, meaning licensed compounding pharmacies may prepare it
Loading supplier information
Sermorelin Dosing Protocol and Schedule
The supplied source reports a nightly subcutaneous titration from 100 mcg up to 400–500 mcg over about 9+ weeks, dosed 30–60 minutes before bed on an empty stomach, drawing on the original 0.2–0.3 mg/day FDA-era label range and published practitioner reviews.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Weeks 1–2 | 100 mcg nightly | FDA-era label context and practitioner reports |
| Weeks 3–4 | 200 mcg nightly | FDA-era label context and practitioner reports |
| Weeks 5–8 | 300 mcg nightly | Practitioner reports |
| Week 9+ | 400–500 mcg nightly (selected cases) | Practitioner reports; not validated by a modern RCT |
| Cycle length | 3–6 months at a target dose | Practitioner reviews |
| Rest structure | 5 nights on / 2 nights off is an alternative reported schedule | Practitioner reports |
The 100–300 mcg range reflects the original FDA-era 0.2–0.3 mg/day adult-context label range. The 400–500 mcg tier and long-term adult anti-aging use were never validated in a large modern randomized controlled trial.
Sermorelin Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled 10 mg vial
Research planning item
Bacteriostatic water, 3 mL per 10 mg vial
Research planning item
U-100 insulin syringes (0.3 mL / 30-unit)
Research planning item
Alcohol prep swabs
Research planning item
Sharps container
Research planning item
Refrigeration for the prepared vial
Research planning item
Baseline and follow-up lab requisitions (IGF-1 and thyroid panel)
Sermorelin Reconstitution Calculator
Vial-format concentration math
Concentration
3.333 mg/mL
Draw volume
0.06 mL
U-100 units
6
Mathematical draws
50
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take Sermorelin: Morning or Night?
Morning or evening?
Nightly, 30–60 minutes before sleep, to align with the body's largest natural GH pulse during early sleep.
With food?
On an empty stomach; most protocols wait at least 60–90 minutes after the last meal, since insulin can blunt the GH response.
Once nightly or split?
Once nightly is the reported standard; no split-dose schedule was identified.
Missed amount?
Practitioner protocols describe skipping a missed dose and resuming the next night rather than doubling up.
Sermorelin Route Comparison
| Format | What is reported | Evidence limit |
|---|---|---|
| Subcutaneous injection | Nightly, typically abdomen, from a reconstituted vial | The FDA-era approved and currently compounded route |
| Other routes | Not established | No published oral, intranasal, or alternative-route human data was identified |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
Sermorelin Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Human plasma half-life | About 11–12 minutes | Explains the need for nightly rather than less-frequent dosing |
| GH pulse duration | Longer than the peptide's own half-life | The triggered GH pulse outlasts sermorelin's presence in plasma |
| Somatostatin feedback | Natural somatostatin rise limits how much GH a single dose can release | Cited as a reason sermorelin is considered lower-risk than direct GH injection |
| Frequency logic | Nightly dosing aligns with the natural sleep-associated GH pulse | Consistent with the short half-life |
Sermorelin Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous | 100 mcg | Nightly, weeks 1–2 | FDA-era label context / practitioner reports | Initiation tier |
| Subcutaneous | 200–300 mcg | Nightly | FDA-era label range (0.2–0.3 mg/day) | Original approved adult-context range |
| Subcutaneous | 400–500 mcg | Nightly, selected cases | Practitioner reports | Not validated by a modern RCT |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
Sermorelin Reconstitution Guide
Concentration: 3.333 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 0.2 mg | 0.06 mL | 6 units |
| 0.4 mg | 0.12 mL | 12 units |
| 0.6 mg | 0.18 mL | 18 units |
- 1.Confirm the exact quantity printed on the vial label (commonly 10 mg).
- 2.Add 3 mL bacteriostatic water per 10 mg vial as the reported standard dilution.
- 3.Clean the vial stopper with an alcohol swab.
- 4.Add the liquid slowly down the vial wall.
- 5.Swirl gently until clear; never shake.
- 6.Inspect for cloudiness, discoloration, or particles and discard anything that is not clear.
- 7.Label the vial with the concentration and preparation date.
- 8.Refrigerate and use within about 28 days, per the reported handling practice.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How Sermorelin Works
Receptor target
Sermorelin is GHRH(1–29), retaining the portion of natural GHRH needed to bind the pituitary GHRH receptor.
Sermorelin Human Trials and FDA Status
Current status · verified September 16, 2026
FDA approved in 1990 as a diagnostic agent and in 1997 as Geref for childhood growth hormone deficiency; Geref was discontinued by Serono Laboratories in 2008 for manufacturing reasons; sermorelin remained on FDA's 503A Category 1 list as of the source review date, meaning licensed compounding pharmacies may prepare it
- Sermorelin was FDA approved in 1990 as a diagnostic agent for evaluating GH secretory capacity.
- It was FDA approved in 1997 as Geref for treatment of childhood growth hormone deficiency.
- Geref was withdrawn from the market by Serono Laboratories in 2008 for manufacturing reasons, not a safety finding.
- No large modern randomized controlled trial has validated adult anti-aging or body-composition dosing beyond the original pediatric and diagnostic approvals.
Who Should Avoid Sermorelin?
This is an evidence-gap and precaution list, not an approved prescribing label.
Active malignancy
GH-axis stimulation is a theoretical concern in growth-sensitive tumors
Pregnancy or breastfeeding
No safety data
Untreated hypothyroidism
Reported to blunt the GH response; thyroid checks were built into the original prescribing pattern
Children outside a diagnosed GH deficiency under clinical care
Original pediatric approval was for a specific diagnosed deficiency
Head trauma or pituitary disorders without clinician oversight
Pituitary function may be affected
Self-directed use without a compounding pharmacy and clinician
No current branded, independently manufactured product exists
Sermorelin Side Effects, Risks and Safety
Injection-site redness or irritationCommon
Important limitation: Consistent with subcutaneous peptide injection generally.
Flushing or warmth after injectionReported
Important limitation: Transient.
HypothyroidismReported in about 6.5% of FDA-era trial participants
Important limitation: Basis for built-in thyroid monitoring.
Headache or dizzinessReported
Important limitation: Uncommon.
Long-term adult-use safetyNot established by a large modern trial
Important limitation: Practitioner reviews only.
Drug interactionsNot comprehensively studied
Important limitation: Use with clinician oversight.
Sermorelin Timeline and Monitoring
Body-composition changes
Usually reported to need 3–6 months.
Lab monitoring points
Baseline, week 6, and week 12 IGF-1 and thyroid panel checks are standard practice in the reviewed sources.
Cycle review
3–6 months at a target dose before reassessment is the reported practitioner pattern.
Sermorelin Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Diagnostic evaluation of GH secretory capacity | FDA approved (historical) | Original 1990 approval basis | Diagnostic use, not a treatment claim |
| Pediatric growth hormone deficiency treatment | FDA approved (historical, discontinued brand) | Original 1997 Geref approval | Product no longer marketed |
| Adult sleep, recovery, or body-composition benefit | Not established by a large modern RCT | Practitioner reviews and reported experience | Not an FDA-approved adult indication |
| Anti-aging claims broadly | Not established | Marketing framing | No large validating trial identified |
Sermorelin Storage and Handling
Lyophilized vial
Refrigerated storage is the reported standard condition; follow the exact product label.
Prepared vial
Refrigerate and use within about 28 days, per the reported handling practice.
Longer cycles
Reported practice is to start a fresh vial roughly every 28 days to respect the reconstituted-solution limit.
Appearance
A clear, colorless solution is expected. Cloudiness, discoloration, or particles mean discard.
Sermorelin Troubleshooting
Solution appears cloudy
Discard it; do not inject.
Calculated syringe units look wrong
Recheck vial quantity, the 3 mL dilution volume, and target dose arithmetic.
A nightly dose is missed
Practitioner protocols report skipping it and resuming the next night rather than doubling up.
GH response seems inadequate
Untreated hypothyroidism can blunt the response; thyroid labs are part of standard monitoring.
Sourcing without a compounding pharmacy
No current independently manufactured branded product exists; work through a licensed 503A or 503B pharmacy and clinician.
Sermorelin Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| Sermorelin | GHRH(1–29) analogue | Historical FDA approval; 503A Category 1 | Discontinued brand, now compounded |
| CJC-1295 | Modified, longer-acting GHRH analogue | Preclinical/community use | 503A Category 2, not compoundable |
| Tesamorelin | GHRH analogue | FDA approved (Egrifta) for HIV-associated lipodystrophy | Different approved indication |
| Ipamorelin | GH secretagogue, ghrelin-receptor pathway | Preclinical/community use | Not FDA approved |
Sermorelin Frequently Asked Questions
What is Sermorelin?
A 29-amino-acid analogue of human GHRH, also called GRF 1-29, that triggers a natural GH pulse from the pituitary.
Is Sermorelin FDA approved?
It was FDA approved in 1990 as a diagnostic agent and in 1997 as Geref for childhood GH deficiency; the branded product was discontinued in 2008 for manufacturing reasons.
Can it still be legally obtained?
As of the source review date it sits on FDA's 503A Category 1 list, meaning licensed compounding pharmacies may prepare it.
What is a common nightly amount?
200–300 mcg subcutaneous nightly is the most commonly reported range, drawing on the original 0.2–0.3 mg/day FDA-era label.
Why is it dosed at night?
To align with the body's largest natural GH pulse during early sleep.
Why on an empty stomach?
Insulin from food can blunt the GH response, so most protocols wait 60–90 minutes after eating.
What is its half-life?
About 11–12 minutes, which is why it is dosed nightly rather than weekly.
Is more always better?
No. Natural somatostatin feedback caps how much GH a single dose can trigger regardless of amount.
What labs are typically checked?
IGF-1 and a thyroid panel at baseline, week 6, and week 12, per practitioner reviews.
Is adult long-term use validated by a large trial?
No large modern randomized controlled trial has validated adult anti-aging or long-term dosing.
What happens if a dose is missed?
Practitioner protocols report skipping it and resuming the next night without doubling up.
Sources and Research
Coverage source
1. Sermorelin protocol coverage source
Titration schedule, reconstitution math, and page coverage; not primary evidence.
Open direct sourceFDA record
2. Geref (sermorelin acetate) FDA approval history
FDA record of the 1990 diagnostic approval and 1997 pediatric GH deficiency approval.
Open direct sourceHuman research
3. Growth hormone-releasing hormone and its analogues in clinical use
Review context on GHRH analogue pharmacology and pulsatile GH release.
Open direct sourceHuman research
4. Sermorelin: a review of its use in the diagnosis and treatment of growth hormone deficiency
Pharmacology and clinical-use review, including half-life and somatostatin feedback context.
Open direct sourceMissing information flagged for review
- Large modern randomized trial for adult dosing beyond the historical pediatric/diagnostic label: Not established
- Validated long-term adult safety data: Not established
- Independently manufactured branded product data since the 2008 discontinuation: Not established
- Standardized adult monitoring protocol beyond practitioner-reported convention: Not established